|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 227.73 USD | +1.32% |
|
+0.22% | -0.33% |
Company Valuation: AbbVie Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 239,371 | 285,707 | 273,605 | 314,021 | 403,830 | 402,352 | - | - |
| Change | - | 19.36% | -4.24% | 14.77% | 28.6% | -0.37% | - | - |
| Enterprise Value (EV) 1 | 306,225 | 339,749 | 320,176 | 375,610 | 463,570 | 456,215 | 446,420 | 433,790 |
| Change | - | 10.95% | -5.76% | 17.31% | 23.42% | -1.59% | -2.15% | -2.83% |
| P/E Ratio | 21x | 24.4x | 57x | 74.4x | 96.8x | 27.9x | 20.7x | 17.4x |
| PBR | 15.5x | 16.6x | 26.5x | 94.8x | -124x | -829x | 53.8x | 22.3x |
| PEG | - | 8.74x | -1x | -6.1x | -77.12x | 0x | 0.6x | 0.9x |
| Capitalization / Revenue | 4.27x | 4.92x | 5.04x | 5.57x | 6.6x | 5.99x | 5.53x | 5.15x |
| EV / Revenue | 5.46x | 5.85x | 5.89x | 6.67x | 7.58x | 6.79x | 6.14x | 5.56x |
| EV / EBITDA | 10.6x | 11x | 12.5x | 15.6x | 18.9x | 13.9x | 12x | 10.6x |
| EV / EBIT | 10.9x | 11.3x | 12.9x | 16.1x | 19.5x | 14.2x | 12.3x | 10.9x |
| EV / FCF | 13.9x | 14x | 14.5x | 21.1x | 26x | 16.6x | 13.8x | 12.9x |
| FCF Yield | 7.18% | 7.14% | 6.89% | 4.75% | 3.84% | 6.02% | 7.26% | 7.78% |
| Dividend per Share 2 | 5.31 | 5.71 | 5.99 | 6.29 | 6.65 | 6.864 | 7.234 | 7.637 |
| Rate of return | 3.92% | 3.53% | 3.87% | 3.54% | 2.91% | 3.01% | 3.18% | 3.35% |
| EPS 2 | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 | 8.167 | 11 | 13.1 |
| Distribution rate | 82.3% | 86.1% | 220% | 263% | 282% | 84% | 65.8% | 58.3% |
| Net sales 1 | 56,122 | 58,054 | 54,318 | 56,334 | 61,160 | 67,225 | 72,705 | 78,078 |
| EBITDA 1 | 29,018 | 30,961 | 25,545 | 24,104 | 24,483 | 32,908 | 37,108 | 40,870 |
| EBIT 1 | 28,215 | 30,183 | 24,793 | 23,340 | 23,721 | 32,028 | 36,180 | 39,795 |
| Net income 1 | 11,542 | 11,836 | 4,863 | 4,278 | 4,226 | 14,855 | 19,309 | 22,342 |
| Net Debt 1 | 66,854 | 54,042 | 46,571 | 61,589 | 59,740 | 53,864 | 44,068 | 31,439 |
| Reference price 2 | 135.40 | 161.61 | 154.97 | 177.70 | 228.49 | 227.73 | 227.73 | 227.73 |
| Nbr of stocks (in thousands) | 1,767,880 | 1,767,880 | 1,765,537 | 1,767,140 | 1,767,385 | 1,766,793 | - | - |
| Announcement Date | 2/2/22 | 2/9/23 | 2/2/24 | 1/31/25 | 2/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E Ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.88x | 6.79x | 13.86x | 3.01% | 402B | |
| 33.15x | 12.05x | 24.81x | 0.6% | 1,010B | |
| 25.74x | 5.93x | 16.13x | 2.22% | 580B | |
| 17.71x | 4.37x | 10.73x | 3.04% | 330B | |
| 53.11x | 4.94x | 20.09x | 2.81% | 294B | |
| 22.78x | 4.74x | 13.47x | 1.85% | 280B | |
| 21.24x | 5.49x | 13.32x | 2.92% | 281B | |
| 12.7x | 4.76x | 9.73x | 3.95% | 197B | |
| 23.09x | 6.16x | 10.76x | 2.84% | 192B | |
| -45x | 5.43x | 29.95x | 2.58% | 156B | |
| Average | 19.24x | 6.07x | 16.29x | 2.58% | 372.3B | |
| Weighted average by Cap. | 25.08x | 7.27x | 17.63x | 2.15% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABBV Stock
- Valuation AbbVie Inc.
Select your edition
All financial news and data tailored to specific country editions
